Jeena Sikho Lifecare Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Revenue surged on service vertical, but margins compressed: Service revenue grew 84% YoY to INR254 crores, driving total revenue to INR469 crores, while PAT margin fell to 19.5% from 21% as heavy Q4 investments in beds, salaries, and rent hit before revenue could follow.
• An asset-light model is now the growth engine: Management unveiled a zero-capex college hospital partnership model and set a 10,000-bed target in 5 years, a pivot that eliminates the capital burden of owned hospitals while adding trained doctors from day one.
• Rate increases and new verticals are the margin recovery plan: A 15% rate hike on big hospitals took effect 1 April, and six new treatment verticals plus a sexual wellness admission package aim to lift occupancy and ticket sizes without raising ARPOB for poorer patients.
• Government receivables and approval delays are the near-term drag: ~450 beds await Clinical Establishment Act approvals, and government payments stretch to 3-8 months, forcing management to throttle government admissions and redirect capacity.
• What to watch next quarter: Whether the April INR60-crore run-rate holds, how fast the 500 recently added beds ramp to target occupancy, and the pace of government bed approvals and receivable recoveries.

The Asset-Light Pivot: College Hospital Partnerships

• Model mechanics: Jeena Sikho takes over existing Ayurvedic college hospitals under a revenue-share plus minimum guarantee arrangement, incurring no capex and no rent until handover. The college provides half the staff, including doctors and nurses, giving immediate access to trained manpower.
• First two agreements: A deal with Saraswati College in Mohali/Chandigarh was set to be signed this week, and a second with Sanskriti University in Vrindavan, Mathura, adds 150 beds. Together these bring ~250 beds with zero investment.
• Pipeline and scale ambition: 650 beds are in the pipeline via this model, and management plans to reach 8,000-10,000 beds in five years exclusively through college tie-ups, tapping into 600 Ayurvedic colleges across India that each graduate 100 doctors annually.
• Pricing strategy for these beds: Rates will be kept lower at INR6,000-7,000 versus INR9,000-10,000 at owned hospitals, explicitly to serve poorer patients while still generating margin through the asset-light structure.

Manish Grover: "In the next 5 years, I will reach 8,000-10,000 beds. I won't open a new one. I will take colleges' beds. I got a new model which doesn't even require 2-3 lakhs. Why will I invest 2-3 lakhs?"

Margin Compression and the Recovery Path

• What drove the PAT margin down to 19.5%: In the last three months of FY25, salary costs rose INR9.9 crores over six months, rent increased INR7.6 crores from new hospital acquisitions, depreciation added INR3 crores, and housekeeping rose INR4 crores. These expenses were loaded before 31 March while the 573 new beds added during the year had not yet begun generating revenue.
• The 15% rate increase lever: Effective 1 April 2025, rates were raised only at the six largest hospitals, now seven with Gurgaon. This deliberately pushes price-sensitive patients toward smaller hospitals while maintaining occupancy at the big facilities, a strategy management says is already working.
• New verticals as volume drivers: Six new treatment verticals launched, including knee pain, back pain, depression, anxiety, and infertility, with early results showing 16 conceptions among women whose IVF had failed. A sexual wellness admission package with 7-day and 14-day stays, claimed as a first in India, starts next month.
• Free liver checkup expansion: The free liver checkup program expanded from two to seven hospitals, with Chandigarh clinic revenue jumping from INR30 lakhs to INR70 lakhs as a direct result of patient inflow.
• Margin target with a caveat: Management is planning for a 25% PAT margin and expects 23-25% next year, but refuses to commit firmly, citing uncontrollable disruptions like the four-day India-Pakistan border closure that stranded patients.

Manish Grover: "No, I can't claim 25%. But the planning that I have made is for a 25% margin. Because there are ups and downs. For example, India-Pakistan. We were stuck for 4 days. We left the patient for 4 days. Then we called him again. I can't say that this will be an act of God."

Bed Capacity, Occupancy, and the Approval Bottleneck

• Bed count trajectory: Total beds reached approximately 2,200 by March 2025 after adding 573 during the year, with 500 of those added in the last three months alone. The FY26 target is 2,800 beds by year-end and 3,000+ by 31 March 2026, including the college partnership beds.
• Occupancy is bifurcated: Overall occupancy sits at 53%, dragged down by newly added beds and hospitals like Gurgaon that lack clinical establishment and NABH certificates. Mature hospitals tell a different story: Dera Bassi and Lucknow run at 80-90%, Mumbai at 70-80%.
• The approval overhang: Approximately 573 beds, of which ~450 are still awaiting government approval, are stuck due to Clinical Establishment Act registration requirements. A recent rule change now demands state-wise doctor registration instead of the previous all-India registration, plus medicine registration, putting the company 15-20 days behind on compliance.
• No specific timeline given for clearance: When pressed on when remaining bed approvals will come, management said only that the process is ongoing and cited pending fire certificates and air pollution certificates as examples, without committing to dates.
• ARPOB stability by design: ARPOB will remain around INR8,200 because management serves poor and middle-class patients, with about 10% receiving free treatment. The 15% rate increase on big hospitals is offset by patient diversion to smaller, lower-priced facilities.

Manish Grover: "If I remove free treatment, then my average will be 85-87 instead of 8200. How do I forget my responsibility? I am also an Indian and I have to help people."

Revenue Run-Rate and FY26 Outlook

• April sets a INR60-crore monthly baseline: April 2025 revenue reached INR60 crores, and management stated that if this run-rate holds, minimum FY26 revenue would be INR720 crores. The benefit of 500 beds added in the last three months began flowing from April onward.
• Profit expectation anchored to the run-rate: Management expects profit of approximately INR130-140 crores next year, assuming the new hospitals generate revenue from this month and the rate increase flows through.
• Service vertical is the growth engine: Service revenue grew 83% YoY to INR254 crores versus 16% growth in product revenue to INR215 crores. Management explicitly prioritizes service over product because service ticket sizes are INR50-60K versus INR5-6K for products, and patient recovery is faster.
• Product vertical as a cash generator: Product sales reached INR215 crores, up from INR186 crores, and the segment is described as a free cash generative revenue system. New products launched include honey, chyawanprash, and India's first Ayurvedic toothpaste without SLS or SMS.
• Government revenue is being deliberately throttled: Government revenue was 24% of the total last year, rose 11% in April, then was reduced. Management has stopped admissions for big government officers due to payment cycles stretching 3-8 months, with some receivables outstanding up to 8 months. INR6 crores in government payments were received after 31 March.

Manish Grover: "If I hold this running, then INR720 crores will be the minimum, right?"

New Business Lines and Product Pipeline

• INJK Water Device: Launched December 2024, the alkaline and magnetic water machine priced at INR15,000 sold INR1.5-1.7 crores per month by March. The device will be placed in clinics for demos to the 40,000 monthly patients.
• OTC business delayed but imminent: The OTC launch was deliberately postponed to focus on hospital expansion and to comply with the 1954 Magic Remedy Act. The first product, a Pet Saffa Pet Shuddhi kit priced at INR960, will launch in Uttar Pradesh within 2-3 months, with a distributor network being built in Lucknow, Kanpur, and Bareilly.
• OTC profit ambition: Management projects that selling 5 lakh pieces per month of the combined Pet and Liver product would yield a net profit of INR10 crores per month within 1-2 years, though no specific addressable market size was provided when asked.
• 10-15 products in the pipeline: Products are finalized, awaiting trademark registration, with media tie-ups secured with Dainik Jagran, Amar Ujala, Hindustan, Punjab Kesari. Five clinical trial products completed, generating INR3 crores in sales in March out of INR55 crores total.
• Dubai expansion underway: One clinic is operational and covering its expenses, neither in profit nor loss, with profitability expected from this month. A second clinic is about to open, and six centers are planned in total. Jeena Sikho International has been formed as a 100% subsidiary for international business, with paperwork to complete in 1-2 months.

Governance and Organizational Build-Out

• Main board migration in progress: The AGM was completed on 30th, and the application for main board listing will be filed. A consultant has given a timeline of three months, targeting August-September for migration. A share split will be executed within this month and the first week of next month.
• Auditor upgrade: E&Y has been finalized as auditor and has already been engaged for a year on management review. The next balance sheet will be audited by E&Y once the first three-month balance sheet is prepared.
• Senior leadership hires: Interviews for CEO and COO positions have been finalized with shortlisted candidates, and appointments are expected within a week, with introductions planned for the next results call. Dr. Eish Sharma, former Ayush Department head in Mauritius, has been appointed for training. Kaushal ji, retired head of Ayush Department Chandigarh, has joined the independent board.
• Acquisition: A company with 85 operational beds and a 178-bed pipeline was purchased using FD money, with benefits expected from April-May. Only INR5-6 lakhs was spent on company formation, with no further investment made yet.

Guidance & Commitments

Key Metrics